Published in Blood Weekly, November 27th, 2003
According to a study from India, "The severity and clinical course of idiopathic thrombocytopenic purpura (ITP) varies from patient to patient. The factors responsible for this variation are not well understood. In this study we attempted to evaluate the role of anti-idiotypic antibodies in the immunoregulation of the disease.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.